FMC CORP

FMC reported a net loss attributable to stockholders of $186.6 million, or $(1.49) per diluted share, for the second quarter of 2026, a significant decline from a net income of $66.7 million, or $0.53 per diluted share, in the prior year. Revenue for the quarter decreased to $867.1 million from $1,050.5 million. The company incurred substantial restructuring and other charges of $222.3 million, primarily due to Project Foundation and an asset impairment related to the India business divestment. FMC also entered a co-exclusive strategic supply and license agreement with Corteva, Inc. for rimisoxafen, receiving a $200 million prepurchase payment.

FMC Corporation reported Q2 2026 revenue of $867 million, a 17% decrease year-over-year, with Adjusted EBITDA of $153 million, down 26%, but above the high end of guidance. Adjusted EPS declined 62% to $0.26. The company lowered its full-year 2026 outlook for revenue, Adjusted EBITDA, and Adjusted EPS, citing a challenging macro environment. FMC also announced strategic actions, including the sale of its India business and a licensing agreement, aiming to generate approximately $1 billion for debt reduction.

FMC Corporation announced a definitive agreement for a strategic minority equity investment from Tessenderlo Group NV, totaling approximately $403.2 million. Tessenderlo will acquire 30,319,166 shares at $13.30 per share, resulting in an approximate 20.0% ownership stake in FMC. The investment will enable FMC to achieve its $1 billion debt paydown target and concludes its strategic options review. Tessenderlo will also gain board representation and observer rights, subject to certain ownership conditions, and will be subject to customary standstill and lock-up provisions.

FMC Corporation entered into Amendment No. 7 to its Fifth Amended and Restated Credit Agreement on June 16, 2026. This amendment facilitates a new supply and license agreement with Corteva Agriscience LLC, allowing FMC to grant Corteva a first priority security interest on certain intellectual property (Rimi IP). This security interest secures a contingent refund obligation tied to a $200 million payment received from Corteva, with existing lenders agreeing to release the Rimi IP as collateral under the Credit Agreement.

FMC Corporation has entered into a framework agreement to sell its underutilized property in Newark, Delaware, to Ercor Elkton, LLC for approximately $114 million in gross cash proceeds. The company plans to leaseback the facilities it actively operates to ensure no disruption to its research operations at the Stine Research Center. The transaction, expected to close in the fourth quarter of 2026, aims to use the proceeds for debt reduction.

FMC Corporation completed a private offering of $1.2 billion aggregate principal amount of its 8.000% Senior Secured Notes due 2031. The Notes were issued at 100% of their principal amount, yielding estimated net proceeds of $1.185 billion. The company intends to use these proceeds to repurchase or redeem its outstanding 3.200% Senior Notes due October 2026, repay borrowings under its credit agreement, and for general corporate purposes.

FMC Corporation announced the pricing of its previously disclosed offering of $1.2 billion aggregate principal amount of 8.000% Senior Secured Notes due 2031. The offering is expected to close on June 5, 2026. The company plans to use the net proceeds to repurchase or redeem its outstanding 3.200% Senior Notes due October 1, 2026, repay existing credit agreement borrowings, and for general corporate purposes, including other debt repayment. The Notes will be secured by first-priority liens on substantially all assets of FMC and its US, Canadian, and Swiss subsidiary guarantors, and equity interests of Singaporean and Dutch subsidiary guarantors.

FMC Corporation announced a proposed private offering of $750.0 million in senior secured notes due 2031. The company intends to use the net proceeds primarily to repurchase or redeem its outstanding 3.200% Senior Notes due October 2026 and to repay borrowings under its existing credit agreement, as well as for general corporate purposes. The notes will be fully guaranteed by various subsidiaries and secured by first-priority liens on company assets.

FMC CORP reported a net loss of $(281.3) million for Q1 2026, a significant increase from $(15.5) million in Q1 2025, with revenue decreasing to $758.6 million. The company amended its Revolving Credit Facility on April 16, 2026, modifying maximum leverage and minimum interest coverage ratios to provide covenant relief through March 2029. Restructuring charges totaled $94.5 million, primarily due to Project Foundation's manufacturing footprint optimization, and the divestment of the India business is ongoing.

FMC Corporation adopted restated By-Laws on April 28, 2026, which include significant updates to its corporate governance framework. A key change is the introduction of a proxy access provision, allowing eligible stockholders to nominate directors for inclusion in the company's proxy materials. To qualify, stockholders must own at least 3% of the common stock for a continuous three-year period. The number of stockholder nominees is capped at the greater of two or 20% of the board, with specific requirements for nomination notices and nominee eligibility.